A number of clinical trials are investigating the side effects, dosage, and efficacy of PD-1 and CTLA-4 monoclonal antibodies for treating patients with HIV- and hepatitis-associated cancers [reviewed in Ref. This evidence concerns the gene PDCD1 and cancer.